Alphapharm, the Australian subsidiary of Mylan, has recalled four batches of EpiPen brand 300µg epinephrine auto-injectors for a potentially defective part after two of the devices failed to activate, according to a report by ABC News, Australia.
The recalled product was manufactured by Meridian Medical Technologies in St. Louis Missouri and the devices have been distributed worldwide.
“The failure of the auto-injector to activate may result in patients not receiving the required dose of adrenaline, resulting in the worsening of symptoms of anaphylaxis or anaphylactic reactions, which could be life-threatening,” the company said.
The affected batches are:
| Batch number | Expiry |
|---|---|
| 5FA665 | April 2017 |
| 5FA6651 | April 2017 |
| 5FA6652 | April 2017 |
| 5FA6653 | April 2017 |
We presume these batches have been in circulation for a while since the expiration dates are imminent.
Alphapharm said: “At this time, EpiPen Jr 150 microgram adrenaline injection syringe auto-injectors and all other batches of EpiPen 300 microgram adrenaline injection syringe auto-injectors are unaffected and are not subject to this recall.”
As of this writing, a recall has not been initiated in the US.
- Alphapharm is recalling several batches of EpiPen 300µg, with an expiry date of April 17 – Australian Journal of Pharmacy
- EpiPen batches recalled over potential failure to activate – ABC News Australia
